Keenova Announces Unaudited Fourth Quarter 2025 Financial Results
PR Newswire —
Robust Fourth-Quarter Performance Driven by Strength in Acthar® Gel1 and XIAFLEX®2 Financial and Operational Performance Exceeded Expectations as Company Completed Transition into Branded Therapeutics Company Hammer Toe Trial Meets Primary Safety Endpoint and Secondary, Exploratory...